• 63°

FDA approves first pre-surgical breast cancer drug

WASHINGTON (AP) — A biotech drug from Roche has become the first medicine approved to treat breast cancer before surgery, offering an earlier approach against one of the deadliest forms of the disease.
The Food and Drug Administration approved Perjeta for women with a form of early-stage breast cancer who face a high risk of having their cancer spread to other parts of the body.
Surgery to remove tumors is usually the first step in treating most forms of cancer. Perjeta is the first drug to be approved as a pre-surgical step.
Doctors hope that using cancer drugs earlier could help shrink tumors, making them easier to remove. In some cases, that could allow women to keep their breasts, rather than having a full mastectomy. Doctors also say that treating the disease at its earliest stages could prevent tumors from returning later, though studies have not yet established that benefit.
“By making effective therapies available to high-risk patients in the earliest disease setting, we may delay or prevent cancer recurrences,” said FDA’s Dr. Richard Pazdur, who directs the agency’s office of cancer products.
Cancer specialists already use several chemotherapy drugs as initial treatments for cancer, but they are not formally approved for the use. The FDA originally approved Perjeta to treat breast cancer that has spread to other parts of the body after surgery.
The FDA granted the drug accelerated approval for its new use based on a study showing women who received the drug as an initial treatment were more likely to be cancer-free 12 weeks later than women who received older drug combinations. Accelerated approval is reserved for drugs that show groundbreaking results for treating life-threatening diseases in early studies.
As a condition of approval, Roche’s Genentech unit must conduct a larger follow-up study showing the drug’s long-term benefits for patients. Generally that means showing that patients lived longer or had a higher quality of life due to taking the drug. Genentech, based in South San Francisco, Calif., has already enrolled about 4,800 patients in the follow-up study, with results expected in 2016.
Dr. Paula Klein, a breast cancer specialist, said she will start prescribing the drug for early-stage patients immediately, but stressed the importance of follow-up data on patient survival.
“This does not yet prove to us that using the antibody in this setting will result in more cures. That is still a hypothesis,” said Klein, who directs the breast cancer program at Continuum Cancer Centers of New York.
The FDA said Monday’s approval was based on a 417-woman study comparing Perjeta in different combinations against older breast cancer treatments. When Perjeta was combined with Herceptin, another Genentech drug, and standard chemotherapy, 39 percent of women saw their cancer reach undetectable levels. Only 21 percent of women experienced the same results from taking Herceptin and chemotherapy alone. After drug treatment all the women received standard breast surgery to remove any cancerous tumors. Genentech says this surgery allowed researchers to confirm the presence or absence of cancer.
Like Herceptin, Perjeta only works in a subset of about 20 percent of breast cancer patients who have tumors that overproduce a protein known as HER-2. This protein causes cancer cells to divide and grow faster than usual.
A spokeswoman for Genentech said a regimen of Perjeta plus Herceptin would cost between $27,000 and $49,000, depending on how long the patient takes the combination. The new Perjeta label will recommend a course of treatment between nine and 18 weeks.
Breast cancer is the second most deadly form of cancer in U.S. women, behind only lung cancer, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute. About 6,000 to 8,000 deaths per year are attributed to the HER-2 form of the disease.
Breast cancer is highly treatable when detected early. More than 98 percent of women who are diagnosed with first-stage breast cancer survive at least five years, according to NCI figures.

Comments

Comments closed.

Coronavirus

Three deaths, 29 new COVID-19 positives reported

Crime

Blotter: Bullet holes found in woman’s Park Avenue apartment

Crime

Man faces assault charges for domestic incident

High School

Photo gallery: Carson girls win West Regional, headed to state championship

High School

High school basketball: Carson girls headed to state championship game

Local

Commissioners set date for public hearing on potential solar energy system rule changes

Health

Two of Rep. Sasser’s bills successfully pass through Health Committee

Local

Rep. Warren’s measure to allow removal of public notices from newspapers put on back burner

China Grove

China Grove Town Council weighs future of previously rejected housing development

Local

Salisbury City Council hears public comments, receives presentation on Main Street reconfiguration

Crime

Blotter: Man charged with felony drug offenses

Nation/World

California crash kills 13 of 25 people crammed into SUV

Nation/World

Biden vows enough vaccines by end of May

Coronavirus

State to vaccinate medically vulnerable starting March 24

Coronavirus

One new death, 20 new COVID-19 positives reported in Rowan

Kannapolis

Kannapolis man dies in moped crash

Crime

Salisbury Police chief addresses K-9 video, says officer separated from animal

Local

Rowan Rescue Squad sets record straight on fundraising typo

Local

City approves DOT agreement, Salisbury Station project could begin next year

Local

County plans to use vulture effigy, enforce violations to remedy animal carcass feeding problem

Education

Two weeks after ending enhanced protocols, Catawba has no COVID-19 cases

News

Council to hear revised version of Downtown Main Street Plan

Local

Veto override of NC school reopening bill fails in Senate

News

Political Notebook: Majority of likely voters, local legislators support school reopening bill